ESR1 and breast cancer: Inhibition of GSK3 and the ensuing inhibition of DNMT1 activity resulted in re-expression of the Androgen Receptor (AR) and Estrogen Receptor (ER) in prostate cancer (PCa) and breast cancer (BCa) cells, respectively.